Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 177-181

  Green, Nancy S ^a   Barral, Sandra ^b  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b Department of Epidemiology   (United States)

Author keywords

BCL11A; Fetal hemoglobin; Genetic epidemiology; Hydroxyurea; Sickle cell disease

Indexed keywords

BETA GLOBIN; HEMOGLOBIN F; HYDROXYUREA; LYMPHOID TRANSCRIPTION FACTOR BCL11A; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CIS TRANS ISOMERISM; DISEASE SEVERITY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOME ANALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; PHARMACOGENETICS; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VALIDATION PROCESS;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CARRIER PROTEINS; FETAL HEMOGLOBIN; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HYDROXYUREA; NUCLEAR PROTEINS;

EID: 78650117667     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22754     Document Type: Review

References (35)

1. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 38: S512-S521.
2. 2006 data. Accessed 4/15/10.
3. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. New Engl J Med 2008; 358: 362-369.
4. Powars DR, Weiss JN, Chan LS, et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984; 63: 921-926.
5. Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: A twin heritability study. Blood 2000; 95: 342-346.
6. Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 2003; 72: 121-126.
7. Bank A. Regulation of human fetal hemoglobin: New players, new complexities. Blood 2006; 107: 435-443.
8. Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 2010; 24: 783-798.
9. Thein SL, Menzel S, Lathrop M, et al. Control of fetal hemoglobin: New insights emerging from genomics and clinical implications. Hum Mol Genet 2009; 18: R216-R223.
10. Pan WH, Lynn KS, Chen CH, et al. Using endophenotypes for pathway clusters to map complex disease genes. Genet Epidemiol 2006; 30: 143-154.
11. Schliekelman P. Statistical power of expression quantitative trait loci for mapping of complex trait loci in natural populations. Genetics 2008; 178: 2201-2216.
12. Gilman JG, Huisman THJ. DNA sequence variation associated with elevated fetal Gg globin production. Blood 1985; 66: 783-787.
13. Nagel RL, Erlingsson S, Fabry ME, et al. The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients. Blood 1991; 77: 1371-1375.
14. Green NS, Fabry ME, Kaptue-Noche L, et al. Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia. Am J Hematol 1993; 44: 145-146.
15. Adeyemo A, Gerry N, Chen G, et al. A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet 2009; 5: e1000564.
16. Jallow M, Teo YY, Small KS, et al. Wellcome Trust Case Control Consortium; Malaria Genomic Epidemiology Network. Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet 2009; 41: 657-665.
17. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci USA 2007; 104: 11346-11351.
18. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007; 39: 1197-1199.
19. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008; 105: 11869-11874.
20. Creary LE, Ulug P, Menzel S, et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One 2009; 4: e4218.
21. Uda M, Galanello R, Sanna S, Lettre G, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008; 105: 1620-1625.
22. Michelson AM. Developmental biology. From genetic association to genetic switch. Science 2008; 322: 1803-1804.
23. Singh H, Pongubala JM, Medina KL. Gene regulatory networks that orchestrate the development of B lymphocyte precursors. Adv Exp Med Biol 2007; 596: 57-62.
24. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009; 460: 1093-1097.
25. Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. Nat Genet 2009; 41: 1191-1198.
26. Sebastiani P, Solovieff N, Hartley SW, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol 2010; 85: 29-35.
27. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: Genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010; 115: 1815-1822.
28. Kumkhaek C, Taylor JG VI, Zhu J, et al. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol 2008; 141: 254-259.
29. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
30. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007; 7: 386-394.
31. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002; 99: 10-14.
32. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363.
33. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148: 932-938.
34. Snyder AR, Zhou J, Deng Z, et al. Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres. Cancer Biol Ther 2009; 8: 1136-1145.
35. Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatr Blood Cancer 2010; 54: 250-255.